Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy

MLA

Ichiro Nakashima, et al. “Optimal Management of Neuromyelitis Optica Spectrum Disorder with Aquaporin-4 Antibody by Oral Prednisolone Maintenance Therapy.” Multiple Sclerosis and Related Disorders, vol. 49, Apr. 2021, p. 102750. EBSCOhost, https://doi.org/10.1016/j.msard.2021.102750.

APA

Ichiro Nakashima, Masashi Aoki, Kazuo Fujihara, Tatsuro Misu, Yoshiki Takai, Hiroshi Kuroda, Toshiyuki Takahashi, Shuhei Nishiyama, & Tetsuya Akaishi. (2021). Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy. Multiple Sclerosis and Related Disorders, 49, 102750. https://doi.org/10.1016/j.msard.2021.102750

Chicago

Ichiro Nakashima, Masashi Aoki, Kazuo Fujihara, Tatsuro Misu, Yoshiki Takai, Hiroshi Kuroda, Toshiyuki Takahashi, Shuhei Nishiyama, and Tetsuya Akaishi. 2021. “Optimal Management of Neuromyelitis Optica Spectrum Disorder with Aquaporin-4 Antibody by Oral Prednisolone Maintenance Therapy.” Multiple Sclerosis and Related Disorders 49 (April): 102750. doi:10.1016/j.msard.2021.102750.